Why US Medicare cuts could stall novel heart failure therapies

The American College of Cardiology is pressing the US Congress and the Centers for Medicare and Medicaid Services to reverse a proposed round of physician fee schedule reductions that would hit cardiovascular specialists harder than most other fields. The campaign argues that compounding payment cuts over several years are pushing cardiology practices towards breaking point, with consequences extending well beyond the United States. For Australian readers who follow cardiology breakthroughs, this matters more than it might first appear.

Heart failure care has changed dramatically in the last decade. Drug classes such as SGLT2 inhibitors and ARNIs, alongside refined device therapies and structured remote monitoring programs, have shifted what cardiologists can offer patients. These advances arrived after years of expensive trials, regulatory submissions, and rollout logistics. Whether they continue to reach the patients who need them quickly depends on reimbursement signals sent to researchers, manufacturers, and clinic operators.

Australia sits downstream of many of these decisions. Local clinicians often wait for international trial readouts, TGA approval, and a Pharmaceutical Benefits Scheme listing before new therapies become routine. When the largest single payer in the world narrows what it pays for, the global strategy of drug and device makers tends to shift, and Australian waiting rooms feel the lag.

The fee schedule decision and cardiology's alarm

The current dispute centres on the US Medicare physician fee schedule, a long list of payment rates the federal government uses to compensate clinicians who treat people aged 65 and over, as well as some younger patients with disabilities. Independent committees review the schedule each year and recommend adjustments to reflect changes in practice costs and the relative value of different services. Cardiology groups have argued that several years of downward adjustments, layered on top of one another, do not match the rising costs of running a practice that employs nurses, sonographers, and advanced practice providers.

The American College of Cardiology has mobilised its members, urging them to share stories about delayed hiring, deferred equipment upgrades, and difficult conversations with patients about access. Campaign materials describe practices that have reduced clinic hours, paused same-day stress testing, or stopped taking new Medicare referrals. While the policy debate is domestic to the United States, the underlying pattern, a payer squeezing specialist fees while the cost of delivering advanced care climbs, is one other health systems watch closely.

Why reimbursement frameworks shape therapy adoption

New heart failure therapies rarely arrive as a finished product. They emerge from research pipelines that take a decade or more to mature, then require a substantial second investment to translate trials into clinical practice. Manufacturers weigh reimbursement certainty heavily when deciding which programmes to fund and where to launch first.

When a major payer signals that it will pay less for the specialist services that prescribe, monitor, and adjust a new therapy, three things tend to happen. Trial sites become harder to staff, because clinicians cannot afford to spend unreimbursed hours on research. Training programmes for new devices or infusions slow down, since practices cannot absorb the cost of releasing staff to attend them. And launch priorities shift towards indications with stronger payment, sometimes leaving heart failure further down the list. The result is a quieter form of rationing that affects patients who never see the policy paper that caused it.

From US trials to Australian waiting rooms

For Australian patients, the chain of dependency is often invisible. A therapy is usually developed and first marketed in the United States, then submitted to the Therapeutic Goods Administration for Australian registration, and finally considered by the Pharmaceutical Benefits Advisory Committee for PBS subsidy. Specialist consultation fees follow a parallel track through the Medicare Benefits Schedule, with rebates set independently of US rates but calibrated against similar assumptions about practice economics.

Several large Australian centres already collaborate with US investigators on heart failure trials. The Alfred's heart failure service in Melbourne, MonashHeart at Monash Health in Clayton, and St Vincent's Hospital Sydney have built reputations as trial sites and early adopters. Their ability to keep attracting commercial sponsors depends on having cardiologists with the time, the supporting staff, and the equipment to run complex protocols. If US fee pressure discourages sponsor investment, fewer multinational trials will open Australian arms, and local patients will find fewer opportunities to access next-generation therapies through study participation.

How slowed adoption could show up in cardiology care

Slowed adoption rarely announces itself. There is no single moment when a therapy becomes unavailable. Instead, the signs are subtler, including a slower update to local guidelines, a longer wait for a clinic to offer a newly approved infusion, or a quieter pipeline of trials recruiting in Australian cities. Heart failure is particularly vulnerable because its treatment relies on a chain of small decisions, each dependent on having time, equipment, and adequately staffed services.

Heart Foundation Australia has flagged similar concerns in recent submissions, noting that rural and remote patients already face long journeys to reach multidisciplinary heart failure teams in Brisbane, Perth, or Sydney. Anything that narrows the pipeline of new therapies widens that gap. A handful of patterns are worth watching for:

• Longer intervals between PBS listing of a new heart failure medicine and its routine appearance in Australian hospital formularies
• A drop in the number of Australian sites activated for pivotal device or drug trials
• More restrictive criteria in private health fund policies for accessing advanced heart failure programs
• Greater out-of-pocket costs for patients seeking specialist time outside fully bulk-billed settings
• A gradual shift of advanced heart failure services towards fewer, larger tertiary centres in capital cities, leaving regional patients with longer travel

US Medicare vs Australia: a reimbursement comparison

Although both countries use the word Medicare, the systems differ in important ways. The Australian version funds a wide range of primary and specialist services for residents and sets rebate levels through the Medicare Benefits Schedule, while subsidised medicines are handled through the Pharmaceutical Benefits Scheme. The US version covers older and disabled Americans through a federal program that pays clinicians according to a fee schedule, with most patients also carrying private insurance or paying out of pocket. The table below sketches the relevant differences for context.

Feature	US Medicare	Australian Medicare
Primary funder of specialist consultations	Federal government via CMS	Federal government via Medicare Benefits Schedule
Drug subsidy pathway	Part D plans, varied by plan	Pharmaceutical Benefits Scheme
Regulatory approval	Food and Drug Administration	Therapeutic Goods Administration
Typical patient cost at point of care	Co-insurance or supplemental premium	Bulk billing or gap fee paid by patient
Recent cardiology fee trajectory	Multi-year downward adjustments under review	Periodic MBS review, generally stable for specialist rebates
Role of private insurance	Central for most non-covered services	Optional, for private hospital and ancillary cover
Key cardiology advocacy channel	American College of Cardiology and individual members	Heart Foundation Australia and the Cardiac Society of Australia and New Zealand

The comparison is not symmetric, but it explains why a US policy decision can ripple outwards. Manufacturers planning a global launch need US reimbursement to work, because US volumes anchor the business case. When that anchor is uncertain, decisions about Australian timing become more cautious.

How Australian clinicians and patients are responding

Australian cardiologists and patient advocates have begun to act on the awareness that overseas policy shapes local care. Several practical steps are gaining traction across the country:

• Joining Heart Foundation Australia's patient registries and advocacy panels so that consumer voices are heard in PBS and MBS reviews
• Asking local cardiologists and GPs about participation in heart failure trials, particularly those based at major metropolitan centres or affiliated rural outreach clinics
• Following consultations by the Pharmaceutical Benefits Advisory Committee and submitting consumer comments when new heart failure therapies are listed for subsidy consideration
• Supporting clinician-led submissions to the Cardiac Society of Australia and New Zealand on workforce and infrastructure concerns tied to advanced heart failure services
• Sharing personal experiences of heart failure care through patient story banks, including those run by Heart Foundation Australia and condition-specific support groups
• Writing to federal MPs about the importance of stable MBS funding for complex cardiology consultations, especially in regional and outer-suburban practices where bulk billing is already under strain

For clinicians, the equivalent response is to stay engaged with the policy plumbing that determines whether a new therapy ever reaches the prescription pad. That means contributing data to local registries, responding to consultation papers, and standing behind patient advocates who carry the message into parliamentary offices.

If you or someone close to you has lived through heart failure treatment in Australia, your story adds weight to the argument that access to novel therapies is worth protecting. The policy debate may be unfolding in Washington, but the consequences reach as far as a cardiology clinic in Fitzroy, a heart failure nurse in Townsville, and a waiting room in Adelaide.